



**Major Milestones  
in Global Health and  
Pharmacovigilance**



**World Health  
Organization**

 **SWISSmedic**

# Preventable Adverse Drug Reaction in pharmacovigilance database


Vu Dinh Hoa

National Drug Information and Adverse Drug Monitoring Center

Hanoi University of Pharmacy

Vietnam

# Introductions




**Preventable ADR**


- ADE: Adverse drug event
- ADR: Adverse drug reaction

Low  
quality/counterfe  
t drugs


Until 2017: 66000 reports in the database



**Fig. 4** Number of ADR reports in Vietnamese database. *SIDCA* Swedish International Development Cooperation Agency, *DAV* Drug Administration of Vietnam, *NPVC* National Pharmacovigilance center, *ADR* Adverse Drug Reaction



# Methods



**Causality assessment:**  
WHO criteria, routine process  
in NPVC

**Preventability assessment:**  
French method:  
Imbs (1998), Olivier (2005) [1]

## Preventability assessment form

Annexe 4 - Fiche d'évaluation de l'évitabilité de EIM Code: VNM.....

Effet indésirable :

Effet indésirable connu? → Non : score inévaluable  
↓ Oui

Erreur dans le circuit du médicament pouvant expliquer directement l'effet indésirable ?  
(cocher 1 ou plusieurs items) → Oui : effet évitable

fabrication       dispensation       prescription  
 administration       transcription       auto - prescription d'un médicament listé  
 problème d'observance

↓ Non


Recommandations\* accessibles à la date de la dernière prescription ou de la dernière prise ?  
(De ..... ) → Non : score non applicable  
↓ Oui

LE MEDICAMENT	Score	Nom du médicament	
<b>A - Respect de recommandations du médicament* (choisir a, b ou c)</b>			
a - Recommandation(s) respectée(s) ; ou : l'absence de prise de précaution n'a joué aucun rôle dans ce cas	+3		
b - Item inévaluable	0		
c - Négligence de(s) recommandation(s) par le prescripteur ou le patient	-5		
<b>LE MALADE</b>			
<b>B - Autre(s) facteur(s) de risque identifié(s) chez ce malade (remplir a, b, c ou d)</b>			
a - Présent(s), facile(s) à détecter (maladies concomitantes ou effets indésirables, association à d'autres médicaments à risque)	-3		
b - Présent(s), difficile(s) à détecter (maladies concomitantes ou effets indésirables, association à d'autres médicaments à risque)	-1		
c - Absent(s)	+2		
d - Item inévaluable	0		

\* C - Adaptation de la prescription aux conditions de vie et à l'environnement du patient (choisir a, b ou c)

Level	Preventability	Score
1	Preventable	-13 to -8 or ME
2	Partly preventable	-7 to -3
3	Not assessable	-2 to +2
4	Not preventable	+3 to +8

1. Therapie. 2005 Jan-Feb;60(1):39-45




## Results

### Patient characteristic and the most common pADR (n=132)

	N (%)
<b>Patient information</b>	
Female (n, %)	65 (49.2)
Age (years)	42.3 ± 21.3
Weight (kg)	50.5 ± 15.5
<b>Health care staff's occupation</b>	
Pharmacists	71 (53.8)
Doctors	25 (18.9)
Others (Nurses, midwives...)	30 (22.7)

- Pharmacist played important role
- Type B ADR are common

Most common pADR	N (%)
Pruritus	34 (25.8)
Rash erythematous	33 (25.0)
Anaphylactic reaction/shock	24 (18.2)
Rash	15 (11.4)
Oedema eyelid	11 (8.3)
Application site reaction	10 (7.6)
Urticaria	10 (7.6)
Fatigue	8 (6.1)



# Results

## Most common drugs/drug groups related to the pADR (n=132)

ATC code	Drug groups	N(%)
J01D	Other betalactams (*)	101 (76.5)
J01M	flouroquinolons	73 (55.3)
J01C	penicilines	22 (16.7)
M01A	NSAIDs	16 (12.1)
J01X	Other antibiotics (**)	10 (7.6)
N02B	Antipyretics and analgesocs (***)	9 (6.8)
J04A	Antituberculosis agents	6 (4.5)


(\*) cephalosporins, monobactams và carbapenems

(\*\*) glycopeptids, polymyxins, imidazols and others

(\*\*\*) acid salycilic and derivatives, pyrazolons, anilids and others

Most common causal drugs	N (%)
Cefotaxim	7 (5.3)
Ciprofloxacin	6 (4.5)
Diclofenac	6 (4.5)
Paracetamol	(4.5)
Moxifloxacin	6 (4.5)
Amoxicilin/sulbactam	5 (3.8)
Ceftazidim	5 (3.8)
Cefoperazon	4 (3.0)

### Antimicrobial agents and NSAIDs




## Results

### Severity of the pADR (N=132)

Level	Severity	N (%)
1	Mild	21 (15.9)
2	Moderate	19 (14.4)
3	Severe	62 (47.0)
4	Life threatening	6 (4.5)
5	Fatal	1 (0.8)
-	Others (*)	23 (17.4)

(\*\*) Lack of information for CTCAE grading scale



# Results

## Suspect reason for pADR (N=132)

Drug use process	Reason for error	N (%)	Involved person
Dispensing	Self medication	11 (8.3)	Patients, Pharmacists
Prescribing	Allergic history/cross allergic	33 (25.5)	Doctors
	Irrational indications	73 (55.3)	
	Inappropriate dose	5 (3.8)	
Preparation	Injection dilution errors	3 (2.3)	Nurses
Administration	Inappropriated route	4 (2.3)	Nurses
	Infusion rate error	2 (1.5)	
	Wrong drug	1 (0.8)	


# Results

## Case:

- Patient aged 89, surgery prophylaxis by UNASYN (ampiciline + sulbactam) 1.5g
- Anaphylactic shock after 4 min: dyspnea; 80/50 mmHg, tachycardia, cold extremities.
- Patient died even after being treated according to the standard anaphylaxis shock guideline.
- **Penicillin allergic history**


A. THÔNG TIN VỀ BỆNH NHÂN			
1. Họ và tên: [redacted]	2. Ngày sinh: 19.2.1921 Hoặc tuổi: 89.T.	3. Giới tính: <input checked="" type="checkbox"/> Nam <input type="checkbox"/> Nữ	4. Cân nặng: 45 kg
B. THÔNG TIN VỀ PHẢN ỨNG CÓ HẠI (ADR)			
5. Ngày xuất hiện phản ứng: 12.05.2014		6. Phản ứng xuất hiện sau bao lâu (tính từ lần dùng cuối cùng của thuốc nghi ngờ): 04 phút	
7. Mô tả biểu hiện ADR		8. Các xét nghiệm liên quan đến phản ứng	
<p>Sau khi tiêm thuốc K. [redacted]</p> <p>BM xuất hiện:</p> <ul style="list-style-type: none"> <li>- Ichó thỏ</li> <li>- Chấn tay lạnh</li> <li>- Mạch nhom nhỏ khó bắt</li> <li>- HA: 80/50 mmHg.</li> <li>- Tron da lạnh có mẩn đỏ</li> </ul>		<p>ghén, nghiện thuốc lá, nghiện rượu, bệnh</p> <p>đã điều trị</p> <ul style="list-style-type: none"> <li>- tăng HA điều trị thường xuyên</li> <li>- <u>Nữ cắt chỉ dò Nhiễm trùng 3 lần</u></li> <li>- <u>Đi ứng penicillin</u></li> </ul> <p>10. Cách xử trí phản ứng:</p> <ul style="list-style-type: none"> <li>- Tiêm Adrenalin 1mg (Tiêm Bắp + Tĩnh Mạch)</li> <li>- Thở oxy</li> <li>- Bóp bóng</li> <li>- EP tim</li> <li>- Đặt ống nội khí quản</li> <li>- Solumedron 4mg (TM)</li> </ul>	
11. Mức độ nghiêm trọng của phản ứng			
<input checked="" type="checkbox"/> Tử vong	<input type="checkbox"/> Nhập viện/Kéo dài thời gian nằm viện	<input type="checkbox"/> Dị tật thai nhi	
<input type="checkbox"/> Đe dọa tính mạng	<input type="checkbox"/> Tàn tật vĩnh viễn/nặng nề	<input type="checkbox"/> Không nghiêm trọng	
12. Kết quả sau khi xử trí phản ứng			
<input type="checkbox"/> Tử vong do ADR	<input type="checkbox"/> Chưa hồi phục	<input type="checkbox"/> Hồi phục có di chứng	<input type="checkbox"/> Không rõ
<input type="checkbox"/> Tử vong không liên quan đến thuốc	<input type="checkbox"/> Đang hồi phục	<input type="checkbox"/> Hồi phục không có di chứng	





## Conclusion

- Determining the preventability (or ME) is possible from spontaneous ADR reports.
- The pADR reflect drug use behaviour: cutaneous reactions were common, related to antibiotics/NSAIDs (most common used drug).
- Common reasons to define preventability: self medication, used historical allergic drug, irrational indication and dose, wrong dilution, wrong route, wrong infusion rate, wrong drug.



Major Milestones  
in Global Health and  
Pharmacovigilance



World Health  
Organization

SWISSmedic

# THANK YOU!!

Tran Thi Khanh Ngan (Msc. Student)

Tran Ngan Ha (Msc.)

Duong Khanh Linh (Msc.)

Vu Dinh Hoa (PhD.)

Nguyen Hoang Anh (PhD.)

